Fenomena Acquired Hemofilia A (AHA) Setelah Infeksi Covid-19: Sebuah Tinjauan Literatur

• Niluh Ayu Sri Saraswati

Vol. 2 No. 1: April 2021 | Pages: 5-8

DOI: 10.47679/makein.202118   Reader: 985 times PDF Download: 295 times

---

Abstract

References

• Abou-Ismail, M., Diamond, A., Kapoor, S., Arafah, Y., & Nayak, L. (2020). The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. https://doi.org/10.1016/j.thromres.2020.06.029

  Cattaneo, M., Bertinato, E., Birocchi, S., Brizio, C., Malavolta, D., & Manzoni, M. (2020). Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thrombophylaxix justified? Thromb Haemost. https://doi.org/10.1055/s-0040-1712097

  Cohen, A., & Kessler, C. (1996). Acquired inhibitors. Bailleres Clin Haematol, 9, 331–354.

  Connors, J., & Levy, J. (2020). COVID-19 and its implications for thrombosis and anticoagulation. Blood, 135(23), 2033–2040.

  Coppola, A., Favaloro, E., & Tufano, A. (2010). Acquired inhibitors of coagulation factors: part I - acquired hemophilia A. Semin Thromb Hemost, 38, 433–446.

  Delgado, J., Jimenez-Yuste, V., & Hernandez-Navarro, F. (2003). Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol, 121, 21–35.

  Franchini, M, Castaman, G., & Coppola, A. (2015). Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus, 13, 498–513.

  Franchini, M, & Lippi, G. (2008). Acquired factor VIII inhibitors. Blood, 112, 250–255.

  Franchini, Massimo, Glingani, C., De Donno, G., Casari, S., Caruso, B., Terenziani, I., Perotti, C., Del Fante, C., Sartori, F., & Pagani, M. (2020). The first case of acquired hemophilia A associated with SARS-CoV-2 infection. American Journal of Hematology, 95(8), E197–E198. https://doi.org/10.1002/ajh.25865

  Franchini, Massimo, Vaglio, S., Marano, G., Mengoli, C., Gentili, S., Pupella, S., & Liumbruno, G. M. (2017). Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology, 22(9), 514–520. https://doi.org/10.1080/10245332.2017.1319115

  Gibson, C., Berliner, N., Miller, A., & Loscalzo, J. (2016). Clinical problem-solving. A bruising loss. N Engl J Med, 375, 76–81.

  Hajra, A., Mathai, S. V., Ball, S., Bandyopadhyay, D., Veyseh, M., Chakraborty, S., Lavie, C. J., & Aronow, W. S. (2020). Management of Thrombotic Complications in COVID-19: An Update. Drugs, 80(15), 1553–1562. https://doi.org/10.1007/s40265-020-01377-x

  Iba, T., Levy, J., Levy, M., Connors, J., & Thachil, J. (2020). Coagulopathy of coronavirus disease 2019. Crit Care Med. https://doi.org/10.1097/CCM.0000000000004458

  Kessler, C., & Knobl, P. (2015). Acquired haemophilia: an overview for clinical practice. Eur J Haematol, 95(81), 36–44.

  Klok, F., Kruip, M., Van Deer Meer, M., Arbous, M., Gommers, D., & Kant, K. (2020). Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an update analysis. Thromb Res. https://doi.org/10.1016/j.thromres.2020.04.041

  Knoebl, P., Marco, P., & Baudo, F. (2012). Demographic and clinical data in acquired hemophilia A: results from the European acquired hemphilia (EACH2) registry. J Thromb Haemost, 10, 622–631. httpd://doi.org/10.1111/j.1538-7836.2012.04654.x.

  Kruse-Jarres, R., Kempton, C. L., Baudo, F., Collins, P. W., Knoebl, P., Leissinger, C. A., Tiede, A., & Kessler, C. M. (2017). Acquired hemophilia A: Updated review of evidence and treatment guidance. American Journal of Hematology, 92(7), 695–705. https://doi.org/10.1002/ajh.24777

  McGonagle, D., O;Donnell, J., Sharif, K., Emery, P., & Bridgewood, C. (2020). Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(20)30121-1

  Olsen, G. M., Rinder, H. M., & Tormey, C. A. (2020). De novo acquired hemophilia as an immune dysregulation phenomenon following SARS‐CoV ‐2 infection . Transfusion, 95(October 2020), 9–10. https://doi.org/10.1111/trf.16254

  Ranucci, M., Ballotta, A., Di Dedda, U., Bayshnikova, E., Dei Poli, M., & Resta, M. (2020). The procagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. https://doi.org/10.1111/jth.14854

  Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 18(4), 844–847.

  Tengborn, L., Baudo, F., & Huth-Kuhne, A. (2012). Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG, 119, 1529–1537.

  Terpos, E., Ntanasis-Stathopoulos, I., Elalamy, I., Kastritis, E., Sergentanis, T., & Politou, M. (2020). Hematological findings and complications of COVID-19. Am J Hematol, 95(7), 834–847. https://doi.org/10.1002/ajh.25829

  Thomas, W., Varley, J., Johnston, A., Symington, E., Robinson, M., & Sheares, K. (2020). Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res, 191, 76–77.

  Werwitzke, S., Geisen, U., & Nowak-Gottl, U. (2016). Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: a data from the GTH-AH 01/2010 study. J Thromb Haemost, 14, 940–947.

  Whyte, C., Morrow, G., Mitchell, J., Chowdary, P., & Murch, N. (2020). Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombotic drugs to treat COVID-19. J Thromb Haemost. https://doi.org/10.1111/jth.14872

Rights and permissions

© The Author(s) 2021
Open Access This article is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0), which permits others to share, adapt, and redistribute the material in any medium or format, even for commercial purposes, provided appropriate credit is given to the original author(s) and the source, a link to the license is provided, and any changes made are indicated. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. To view a copy of this license, visit https://creativecommons.org/licenses/by-sa/4.0/.